Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Citrials Inc

Neither a doctor nor a teaching hospital

Research payments

$4,511,955

999 payments

Through program year 2024, Citrials Inc is reported as receiving $4,511,955 in research payments, across 999 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $8,508 3
2023 Research $118,697 19
2022 Research $58,728 8
2021 Research $768,930 505
2020 Research $1,771,385 324
2019 Research $1,785,707 140

Breakdown

Who paid Research payments · program years 2019–2024
  1. Allergan Inc. $1,165,442 113 payments
  2. Teva Pharmaceuticals USA, Inc. $1,141,292 57 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $725,613 18 payments
  4. Sage Therapeutics, Inc. $389,577 36 payments
  5. ITI, Inc. $294,023 455 payments
  6. Hoffmann-La Roche Limited $212,310 32 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $194,912 2 payments
  8. Avanir Pharmaceuticals, Inc. $125,749 19 payments
  9. ACADIA Pharmaceuticals Inc $121,071 179 payments
  10. Eisai Inc. $71,562 72 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $1,141,292 57 payments
  2. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $588,760 48 payments
  3. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $387,405 34 payments
  4. Protocol 331-201-00081 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $372,954 3 payments
  5. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $306,634 27 payments
  6. An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia $294,023 455 payments
  7. Taar1 4 for Negative Symptoms $216,935 36 payments
  8. PoCC dose finding in Mild to Moderate AD $194,912 2 payments
  9. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $138,613 24 payments
  10. 18-Avp-786-207 $117,749 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record